Document:

Form of Change in Control Severance Agreement

 Exhibit 10.21 
 E2OPEN, INC. 
 CHANGE IN CONTROL SEVERANCE AGREEMENT 

This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between
                     (“Executive”) and E2open, Inc., a Delaware corporation (the “Company”), effective as of
                    , 201     (the “Effective Date”). 

RECITALS 
 1. It is expected that the Company from time to time will consider the possibility of an acquisition by another company or other change in control. The Compensation Committee of the Board of Directors of
the Company (the “Committee”) recognizes that such considerations can be a distraction to Executive and can cause Executive to consider alternative employment opportunities. The Committee has determined that it is in the best interests of
the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such a termination of employment or the occurrence of a Change in
Control of the Company. 
 2. The Committee believes that it is in the best interests of the Company and its
stockholders to provide Executive with an incentive to continue his or her employment and to motivate Executive to maximize the value of the Company for the benefit of its stockholders. 

3. The Committee believes that it is imperative to provide Executive with certain severance benefits upon
Executive’s termination of employment. These benefits will provide Executive with enhanced financial security, incentive and encouragement to remain with the Company. 

4. Certain capitalized terms used in the Agreement are defined in Section 5 below. 

AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows: 
 1. Term of Agreement. This Agreement will have an initial term of three (3) years commencing on the Effective Date (the “Initial Term”), subject to earlier termination as provided in
this Agreement. On each third annual anniversary of the Effective Date, this Agreement will renew automatically for an additional three (3) year term (each an “Additional Term”), unless either party provides the other party with
written notice of non-renewal or the Agreement is modified, in each case within the ninety (90) days prior to the date of automatic renewal, in all cases subject to earlier termination in accordance with the provisions of Section 3 and the
final sentence of this Section 1; provided, however, that if during such ninety (90) day period the Company is actively involved in negotiations that if consummated would result in a Change in Control of the Company, no changes may be made
to the Agreement except with Executive’s express written consent, subject to earlier termination in accordance with the provisions of Section 3 and the final sentence of this Section 1.

  
 1 

 
Notwithstanding the foregoing provisions of this Section 1, if a Change in Control occurs when there are fewer than twelve (12) months remaining during the Initial Term or an Additional
Term, the term of this Agreement will extend automatically through the date that is twelve (12) months following the Closing (as defined below). If Executive becomes entitled to benefits under Section 3 during the term of this Agreement,
the Agreement will not terminate until all of the obligations of the parties hereto with respect to this Agreement have been satisfied. 
 2. At-Will Employment. The Company and Executive acknowledge that Executive’s employment is and will continue to be at-will, as defined under applicable law. 

3. Severance Benefits. 
 (a) Termination without Cause or Other than Death or Disability or Resignation for Good Reason Outside of the Change in Control Period. If (x) the Company terminates Executive’s
employment with the Company for a reason other than Cause or Executive’s death or disability or (y) if Executive resigns from such employment for Good Reason, and in each case, such termination occurs outside of the Change in Control
Period, and in each case, Executive signs and does not revoke a release of claims agreement with the Company (including an agreement not to disparage the Company, non-solicit provisions and other standard terms and conditions) in a form reasonably
acceptable to the Company (the “Release”), and provided that the Release becomes effective no later than sixty (60) days following the termination date (such deadline, the “Release Deadline”), then, in each case subject to
this Section 3, Executive will receive the following severance from the Company: (i) continuing payments of severance pay at a rate equal to Executive’s annual base salary as in effect on the date of Executive’s termination, for
[twelve (12) / six (6)] months from the date of such termination, and (ii) continuing payments of severance pay of $1,900 for [twelve (12) / six (6)] months from the date of such termination both of which will be paid in accordance
with the Company’s standard payroll procedures. The payments of clause (ii) of the prior sentence are intended to defray costs to Executive associated with continued health care coverage for Executive and Executive’s eligible
dependents; however, Executive may use such funds in any manner Executive sees fit. 
 (b) Termination
without Cause or Other than Death or Disability or Resignation for Good Reason During the Change in Control Period. If, during the Change in Control Period, (x) the Company terminates Executive’s employment with the Company for a
reason other than Cause or Executive’s death or disability or (y) Executive resigns from such employment for Good Reason, and in each case, Executive signs and does not revoke a Release, and provided that such Release becomes effective by
the Release Deadline, then, in each case subject to this Section 3, Executive will receive the following severance from the Company: 
 (i) Severance Payment. Executive will receive continuing payments of severance pay at a rate equal to Executive’s annual base salary as in effect on the date of Executive’s termination,
for [twelve (12) / six (6)] months from the date of such termination, which will be paid in accordance with the Company’s standard payroll procedures, and (ii) continuing payments of severance pay of $1,900 for [twelve (12) / six
(6)] months from the date of such termination, which will be paid in accordance with the Company’s standard payroll procedures. The payments of clause (ii) of the prior sentence are intended to defray costs to Executive associated with
continued health 

  
 2 

 
care coverage for Executive and Executive’s eligible dependents; however, Executive may use such funds in any manner Executive sees fit. For avoidance of doubt, the payments under this
Section 3(b)(i) are in place of and not in addition to, any payments to which Executive may have become entitled under Section 3(a). To the extent Executive began receiving payment under such section, and, due to a Change in Control,
becomes eligible for payments under this Section 3(b)(i), the payments previously made under Section 3(a) shall be deemed to have been made under this Section 3(b)(i). 

(ii) Equity Awards. Any equity awards (including, without limitation, any awards of stock options, restricted
stock, restricted stock units, and/or performance shares or units) outstanding as of the date of such termination will vest in full and, to the extent applicable, become exercisable, as to 100% of the unvested portion of the award; provided,
however, that (x) the treatment, including acceleration of vesting, if any, of each equity award with performance-based vesting (“Performance-Based Awards”) will be determined based on the terms and conditions (including definitions)
of the equity award agreement governing such performance-based award (each, a “Performance-Based Award Agreement”) and not this Section 3, and (y) the treatment, including acceleration of vesting, if any, of each equity award
granted with only time-based vesting that is outstanding as of the Effective Date (each, an “Outstanding Time-Based Award”) will be determined based on the terms and conditions (including definitions) of the equity award agreement and
other Company arrangement(s) that are in effect as of the Effective Date (including, but not limited to, change of control agreements, offer letters and actions of the Board of Directors of the Company or any of its committees, as each may be
amended from time to time) governing such time-based award (together, the “Time-Based Award Arrangements”) and not this Section 3). 

(c) Timing of Payments. If the Release does not become effective by the Release Deadline,
Executive will forfeit any rights to severance or benefits under this Agreement. In no event will severance payments or benefits be paid or provided until the Release actually becomes effective and any severance amounts or benefits otherwise payable
between Executive’s termination date and the date the Release becomes effective and irrevocable will be paid on the date the Release becomes effective and irrevocable (or, if later, with respect to the Equity Award Acceleration, on the date of
the Closing, if the date of Executive’s termination of employment occurred within the Change in Control Period but prior to the Closing). Any severance payments or benefits under this Agreement that would be considered Deferred Payments will
not commence until (x) the sixtieth (60th) day
following Executive’s separation from service (or, if later, with respect to the Equity Award Acceleration, if the date of Executive’s termination of employment occurred within the Change in Control Period but prior to the Closing, on the
date of the Closing), or (y) if later, such time as required by Section 3(g). Except as required by Section 3(g), any installment payments that would have been made to Executive during the sixty (60) day period immediately
following Executive’s separation from service but for the sixtieth (60th) day payment requirement of the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive’s separation from service and the remaining payments shall be made as provided in
this Agreement. In no event shall Executive have discretion to determine the taxable year of payment of any Deferred Payments. 
 (d) Voluntary Resignation; Termination for Cause. If Executive’s employment with the Company terminates (i) voluntarily by Executive (other than for Good Reason) or (ii) for

  
 3 

 
Cause by the Company, then Executive will not be entitled to receive severance or other benefits except for those (if any) as may then be established under the Company’s then existing
severance and benefits plans and practices or pursuant to other written agreements with the Company. 
 (e)
Disability; Death. If the Company terminates Executive’s employment as a result of Executive’s disability, or Executive’s employment terminates due to his or her death, then Executive will not be entitled to receive any other
severance or other benefits except for those (if any) as may then be established under the Company’s then existing written severance and benefits plans and practices or pursuant to other written agreements with the Company. 

(f) Exclusive Remedy. Except as provided by Section 3(b)(ii), in the event of a termination of
Executive’s employment as set forth in Section 3 of this Agreement, the provisions of Section 3 are intended to be and are exclusive and in lieu of and supersede any other rights or remedies to which Executive or the Company otherwise
may be entitled, whether at law, tort or contract or in equity, or under this Agreement (other than the payment of accrued but unpaid wages, as required by law, and any unreimbursed reimbursable expenses). Except as provided by
Section 3(b)(ii), Executive will be entitled to no benefits, compensation or other payments or rights upon a termination of employment other than those benefits expressly set forth in Section 3 of this Agreement. 

(g) Section 409A. 
 (i) Notwithstanding anything to the contrary in this Agreement, no severance benefits payable to Executive, if any, pursuant to this Agreement that, when considered together with any Deferred Payments
will be payable until Executive has a “separation from service” within the meaning of Section 409A. Similarly, no severance payable to Executive, if any, pursuant to this Agreement that otherwise would be exempt from Section 409A
pursuant to Treasury Regulation Section 1.409A-1(b)(9) will be payable until Executive has a “separation from service” within the meaning of Section 409A. 

(ii) Notwithstanding anything to the contrary in this Agreement, if Executive is a “specified employee” within
the meaning of Section 409A at the time of Executive’s separation from service (other than due to death), any Deferred Payments that otherwise are payable within the first six (6) months following Executive’s separation from
service will become payable on the date six (6) months and one (1) day following the date of Executive’s separation from service. All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule
applicable to each payment or benefit. Notwithstanding anything herein to the contrary, in the event of Executive’s death following Executive’s separation from service but prior to the six (6) month anniversary of Executive’s
separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive’s death and all other Deferred Payments will be payable in
accordance with the payment schedule applicable to each payment or benefit. Each payment, installment and benefit payable under the Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury
Regulations. 

  
 4 

 (iii) Any amount paid under this Agreement that satisfies the requirements
of the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of this Agreement. 

(iv) Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from
service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Payments for purposes of this Agreement. 

(v) The foregoing provisions are intended to comply with, or be exempt from, the requirements of Section 409A so
that none of the severance benefits to be provided under the Agreement will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to so comply or be exempt. Executive and
the Company agree to work together in good faith to consider amendments to the Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to
actual payment to Executive under Section 409A. In no event will the Company reimburse Executive for any taxes that may be imposed on Executive as a result of Section 409A. 

(h) Other Requirements. Executive’s receipt of any payments or benefits under this Section 3 will be
subject to Executive continuing to comply with the terms of any confidential information agreement executed by Executive in favor of the Company and the provisions of this Agreement. 

4. Limitation on Payments. In the event that the severance benefits provided for in this Agreement or otherwise
payable to Executive (i) constitute “parachute payments” within the meaning of Section 280G of the Code and (ii) but for this Section 4, would be subject to the excise tax imposed by Section 4999 of the Code, then
Executive’s severance benefits under Section 3 will be either: 
  

	 	(a)	 delivered in full, or 

  

	 	(b)	 delivered as to such lesser extent which would result in no portion of such severance benefits being subject to excise tax under Section 4999
of the Code, 

 whichever of the foregoing amounts, taking into account the applicable federal, state and
local income taxes and the excise tax imposed by Section 4999, results in the receipt by Executive on an after-tax basis, of the greatest amount of severance benefits, notwithstanding that all or some portion of such severance benefits may be
taxable under Section 4999 of the Code. If a reduction in severance and other benefits constituting “parachute payments” is necessary so that benefits are delivered to a lesser extent, reduction will occur in the following order:
(i) reduction of cash payments, which shall occur in reverse chronological order such that the cash payment owed on the latest date following the occurrence of the event triggering such excise tax will be the first cash payment to be reduced;
(ii) reduction of acceleration of vesting of equity awards, which shall occur in the reverse order of the date of grant for such stock awards (i.e., the vesting of the most recently granted stock awards will be reduced first); and
(iii) reduction of other benefits paid or provided to 

  
 5 

 
the Executive, which shall occur in reverse chronological order such that the benefit owed on the latest date following the occurrence of the event triggering such excise tax will be the first
benefit to be reduced. If more than one equity award was made to the Executive on the same date of grant, all such awards shall have their acceleration of vesting reduced pro rata. In no event shall the Executive have any discretion with respect to
the ordering of payment reductions. 
 Unless the Company and Executive otherwise agree in writing, any
determination required under this Section 4 will be made in writing by a nationally recognized firm of independent public accountants selected by the Company (the “Accountants”), whose determination will be conclusive and binding upon
Executive and the Company for all purposes. For purposes of making the calculations required by this Section 4, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good
faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive will furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a
determination under this Section. The Company will bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 4. 

5. Definition of Terms. For purposes of this Agreement, the following terms referred to in this Agreement will
have the following meanings: 
 (a) Cause. “Cause” means: 

(i) Any act of material fraud or dishonesty taken by Executive in connection with Executive’s responsibilities as
an employee; 
 (ii) Executive’s improper disclosure of any Company confidential information; 

(iii) Executive being convicted of, or accepting a plea of “guilty” or “no contest” to, a felony
under the laws of the U.S. or any state thereof; 
 (iv) An intentional act by Executive which constitutes
misconduct; 
 (v) Executive’s continued material failure to perform his or her employment duties after
Executive has received a written demand of performance from the Company which specifically sets forth the factual basis for the Company’s belief that Executive has not substantially performed his or her duties and has failed to cure such
non-performance to the Company’s satisfaction within thirty (30) days after receiving such notice; 

(vi) An act by Executive that constitutes (A) a material breach of any agreement between Executive and the Company
or (B) a material failure to comply with the Company’s written policies or rules, in each case under this clause (vi) if such breach or failure has not been cured by Executive within thirty (30) days after written notification by
the Company to Executive of such breach or failure; 

  
 6 

 (vii) Executive’s failure to cooperate in good faith with a
governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested the Executive’s cooperation. 
 For purposes of this definition, “Company” shall be interpreted to include any parent, subsidiary, affiliate or successor thereto, if appropriate. 

(b) Change in Control. “Change in Control” means the occurrence of any of the following: 

(i) Change in Ownership of the Company. A change in the ownership of the Company which occurs on the date that
any one person, or more than one person acting as a group (“Person”), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the
Company; provided, however, that for purposes of this subsection (i), the acquisition of additional stock by any one Person, who is considered to own more than 50% of the total voting power of the stock of the Company will not be considered a Change
in Control; or 
 (ii) Change in Effective Control of the Company. A change in the effective control of
the Company which occurs on the date that a majority of members of the Board (each, a “Director”) is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members
of the Board prior to the date of the appointment or election. For purposes of this subsection (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will
not be considered a Change in Control; or 
 (iii) Change in Ownership of a Substantial Portion of the
Company’s Assets. A change in the ownership of a substantial portion of the Company’s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most
recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition
or acquisitions; provided, however, that for purposes of this subsection (iii), the following will not constitute a change in the ownership of a substantial portion of the Company’s assets: (A) a transfer to an entity that is controlled by
the Company’s stockholders immediately after the transfer, or (B) a transfer of assets by the Company to: (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company’s
stock, (2) an entity, 50% or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3) a Person, that owns, directly or indirectly, 50% or more of the total value or voting power of all the
outstanding stock of the Company, or (4) an entity, at least 50% of the total value or voting power of which is owned, directly or indirectly, by a Person described in this subsection (iii)(B)(3). For purposes of this subsection (iii), gross
fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. 

  
 7 

 For purposes of this definition of Change in Control, persons will be
considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. 

Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a
change in control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be
promulgated thereunder from time to time. 
 Further and for the avoidance of doubt, a transaction will not
constitute a Change in Control if: (i) its sole purpose is to change the state of the Company’s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the
persons who held the Company’s securities immediately before such transaction. 
 (c) Change in Control
Period. “Change in Control Period” means the period beginning three (3) months prior to, and ending twelve (12) months following, a Closing. 

(d) Closing. “Closing” means the closing of a transaction constituting a Change in Control. 

(e) Deferred Payments. “Deferred Payments” means any severance pay or benefits to be paid or provided to
Executive (or Executive’s estate or beneficiaries) pursuant to this Agreement and any other severance payments or separation benefits, that in each case, when considered together, are considered deferred compensation under Section 409A.

 (f) Equity Award Acceleration. “Equity Award Acceleration” means the equity award
acceleration provided under Section 3(b)(ii). 
 (g) Good Reason. “Good Reason” means
Executive’s termination of employment within thirty (30) days following the expiration of any cure period (discussed below) following the occurrence of one or more of the following, without Executive’s express written consent:

 (i) A material reduction in Executive’s base compensation as in effect immediately prior to such
reduction, but not including a substantially similar reduction that applies to all similarly-situated executives; 
 (ii) The assignment to Executive of any duties or responsibilities, or the material reduction of or the removal from, Executive’s duties, position, authority or responsibilities, in each case which
results in a material diminution in Executive’s authority, duties, or responsibilities with the Company in effect immediately prior to such assignment, reduction or removal; [to be included in agreement for President and Chief Executive
Officer and for Chief Financial Officer and as otherwise determined by the Compensation Committee: for purposes of clarification, should the Company be acquired and made part of a larger entity, whether as a subsidiary, business unit or
otherwise and the Executive, by virtue of such event, experiences a material diminution in Executive’s authority, duties, or responsibilities (for example, but not by way of limitation, if the [Chief Executive Officer / Chief Financial Officer]
of the Company remains the 

  
 8 

 
[Chief Executive Officer / Chief Financial Officer] of the Company following a Change in Control where the Company becomes a wholly owned subsidiary of the acquirer, but the Executive is not made
the [Chief Executive Officer / Chief Financial Officer] of the acquiring corporation), such material diminution will constitute “Good Reason” under this subsection;] 

(iii) A material change in the geographic location of Executive’s primary work facility or location; provided, that
a relocation of twenty-five (25) miles or less from Executive’s then present location or to Executive’s home as his or her primary work location will not be considered a material change in geographic location; or 

(iv) the failure of the Company to obtain the assumption of this Agreement by a successor, which would constitute a
material breach of this Agreement. 
 In order for an event to qualify as Good Reason, Executive must not
terminate employment with the Company without first providing the Company with written notice of the acts or omissions constituting the grounds for “Good Reason” within ninety (90) days of the initial existence of the grounds for
“Good Reason” and a reasonable cure period of not less than thirty (30) days following the date of such notice, and such grounds must not have been cured during such time. 

(h) Section 409A. “Section 409A” means Section 409A of the Internal Revenue Code of 1986, as
amended (the “Code”) and the final regulations and any guidance promulgated thereunder. 
 (i)
Section 409A Limit. “Section 409A Limit” means two (2) times the lesser of: (i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during the Executive’s taxable year
preceding the Executive’s taxable year of Executive’s termination of employment as determined under, and with such adjustments as are set forth in, Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service
guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which Executive’s employment is terminated. 

6. Successors. 
 (a) The Company’s Successors. Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of
the Company’s business and/or assets will assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such
obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” will include any successor to the Company’s business and/or assets which executes and delivers the assumption agreement described in
this Section 6(a) or which becomes bound by the terms of this Agreement by operation of law. 
 (b)
Executive’s Successors. The terms of this Agreement and all rights of Executive hereunder will inure to the benefit of, and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors,
heirs, distributees, devisees and legatees. 

  
 9 

 7. Notice. 

(a) General. Notices and all other communications contemplated by this Agreement will be in writing and will be
deemed to have been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid or when delivered by a private courier service such as UPS, DHL or Federal Express that has
tracking capability. In the case of Executive, mailed notices will be addressed to him or her at the home address which he or she most recently communicated to the Company in writing. In the case of the Company, mailed notices will be addressed to
its corporate headquarters, and all notices will be directed to the Chief Financial Officer of the Company. 

(b) Notice of Termination. Any termination by the Company for Cause or by Executive for Good Reason or as a result
of a voluntary resignation will be communicated by a notice of termination to the other party hereto given in accordance with Section 7(a) of this Agreement. Such notice will indicate the specific termination provision in this Agreement relied
upon, will set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination under the provision so indicated, and will specify the termination date (which will be not more than thirty (30) days after the
giving of such notice). The failure by Executive to include in the notice any fact or circumstance which contributes to a showing of Good Reason will not waive any right of Executive hereunder or preclude Executive from asserting such fact or
circumstance in enforcing Executive’s rights hereunder. 
 8. Arbitration.  

(a) The Company and Executive each agree that any and all disputes arising out of the terms of this Agreement,
Executive’s employment by the Company, Executive’s service as an officer or director of the Company, or Executive’s compensation and benefits, their interpretation and any of the matters herein released, will be subject to binding
arbitration under the arbitration rules set forth in California Code of Civil Procedure Sections 1280 through 1294.2, including Section 1281.8 (the “Act”), and pursuant to California law. Disputes that the Company and Executive agree
to arbitrate, and thereby agree to waive any right to a trial by jury, include any statutory claims under local, state, or federal law, including, but not limited to, claims under Title VII of the Civil Rights Act of 1964, the Americans with
Disabilities Act of 1990, the Age Discrimination in Employment Act of 1967, the Older Workers Benefit Protection Act, the Sarbanes-Oxley Act, the Worker Adjustment and Retraining Notification Act, the California Fair Employment and Housing Act, the
Family and Medical Leave Act, the California Family Rights Act, the California Labor Code, claims of harassment, discrimination, and wrongful termination, and any statutory or common law claims. The Company and Executive further understand that this
agreement to arbitrate also applies to any disputes that the Company may have with Executive. However, claims for workers’ compensation benefits and unemployment insurance (or any other claims where mandatory arbitration is prohibited by law)
are not covered by this arbitration agreement, and such claims may be presented by the Executive to the appropriate court or government agency. 
 (b) Procedure. The Company and Executive agree that any arbitration will be administered by Judicial Arbitration & Mediation Services, Inc. (“JAMS”), pursuant to its

  
 10 

 
Employment Arbitration Rules & Procedures (the “JAMS Rules”). The Arbitrator will have the power to decide any motions brought by any party to the arbitration, including
motions for summary judgment and/or adjudication, motions to dismiss and demurrers, and motions for class certification, prior to any arbitration hearing. The Arbitrator will have the power to award any remedies available under applicable law, and
the Arbitrator will award attorneys’ fees and costs to the prevailing party, except as prohibited by law. The Company will pay for any administrative or hearing fees charged by the Arbitrator or JAMS except that Executive will pay any filing
fees associated with any arbitration that Executive initiates, but only so much of the filing fees as Executive would have instead paid had he or she filed a complaint in a court of law. The Arbitrator will administer and conduct any arbitration in
accordance with California law, including the California Code of Civil Procedure, and the Arbitrator will apply substantive and procedural California law to any dispute or claim, without reference to rules of conflict of law. To the extent that the
JAMS Rules conflict with California law, California law will take precedence. The decision of the Arbitrator will be in writing. Any arbitration under this Agreement will be conducted in San Mateo County, California. 

(c) Remedy. Except as provided by the Act and this Agreement, arbitration will be the sole, exclusive, and final
remedy for any dispute between Executive and the Company. Accordingly, except as provided for by the Act and this Agreement, neither Executive nor the Company will be permitted to pursue court action regarding claims that are subject to arbitration.

 (d) Administrative Relief. Executive understands that this Agreement does not prohibit him or her from
pursuing any administrative claim with a local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, including, but not limited to, the Department of Fair Employment and
Housing, the Equal Employment Opportunity Commission, the National Labor Relations Board, or the Workers’ Compensation Board. This Agreement does, however, preclude Executive from pursuing court action regarding any such claim, except as
permitted by law. 
 (e) Voluntary Nature of Agreement. Each of the Company and Executive acknowledges
and agrees that such party is executing this Agreement voluntarily and without any duress or undue influence by anyone. Executive further acknowledges and agrees that he or she has carefully read this Agreement and has asked any questions needed for
him or her to understand the terms, consequences, and binding effect of this Agreement and fully understands it, including that Executive is waiving his or her right to a jury trial. Finally, Executive agrees that he or she has
been provided an opportunity to seek the advice of an attorney of his or her choice before signing this Agreement. 
 9. Miscellaneous Provisions. 
 (a) No Duty to
Mitigate. Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor will any such payment be reduced by any earnings that Executive may receive from any other source. 

(b) Waiver. No provision of this Agreement will be modified, waived or discharged unless the modification, waiver
or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver by either 

  
 11 

 
party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party will be considered a waiver of any other condition or provision or of the same
condition or provision at another time. 
 (c) Headings. All captions and section headings used in this
Agreement are for convenient reference only and do not form a part of this Agreement. 
 (d) Entire
Agreement. Except as provided by the following sentence, this Agreement constitutes the entire agreement of the parties hereto and supersedes in their entirety all prior representations, understandings, undertakings or agreements (whether oral
or written and whether expressed or implied) of the parties, including but not limited to any severance or change of control-related severance or acceleration provisions that are included in any offer letter, employment agreement, secondment
agreement or change of control agreement [, as well as [title of any additional agreements that are intended to be superseded by this Agreement]] entered into between Executive and the Company prior to the date of this Agreement with respect to the
subject matter hereof. Notwithstanding the foregoing or anything in this Agreement to the contrary, (x) with respect to the treatment of Performance-Based Awards, the applicable Performance-Based Award Agreements will govern and will not be
superseded by this Agreement, and (y) with respect to the treatment of Outstanding Time-Based Awards, the applicable Time-Based Award Arrangements will govern and will not be superseded by this Agreement. With respect to Company equity awards
granted to Executive on or after the date of this Agreement (other than equity awards with performance-based vesting), the acceleration of vesting provisions provided herein (and related timing of payment provisions) will apply to such equity awards
except to the extent otherwise explicitly provided in the applicable equity award agreement by reference to this Agreement. No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless in writing and
signed by duly authorized representatives of the parties hereto and which specifically mention this Agreement. 

(e) Choice of Law. The validity, interpretation, construction and performance of this Agreement will be governed
by the laws of the State of California (with the exception of its conflict of laws provisions). Any claims or legal actions by one party against the other arising out of the relationship between the parties contemplated herein (whether or not
arising under this Agreement) will be commenced or maintained in any state or federal court located in San Mateo County, California, and Executive and the Company hereby submit to the jurisdiction and venue of any such court. 

(f) Severability. The invalidity or unenforceability of any provision or provisions of this Agreement will not
affect the validity or enforceability of any other provision hereof, which will remain in full force and effect. 
 (g) Withholding. All payments made pursuant to this Agreement will be subject to withholding of applicable income and employment taxes. 

(h) Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but
all of which together will constitute one and the same instrument. 

  
 12 

 [Signature Page to Follow] 

  
 13 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the
case of the Company by its duly authorized officer, as of the day and year first set forth above. 
  

					
	 COMPANY
	 	 E2OPEN, INC.

			
		 	 By:
	 	  

			
		 	 Title:
	 	  

			
	 EXECUTIVE
	 	 By:
	 	  

			
		 	 Title:
	 	  

  
 14Amended and Restated Warrant issued pursuant to the Loan and Security Agreement

 Exhibit 4.2 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD,
PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS. 
 AMENDED AND RESTATED WARRANT TO PURCHASE STOCK 

 

					
		 	Corporation:	  	HYPERION THERAPEUTICS, INC., a Delaware corporation
		 	Number of Shares:	  	1,671
		 	Class of Securities:	  	Common Stock
		 	Initial Exercise Price:	  	$314.13 per share
		 	Original Issue Date:	  	October 2, 2007
		 	 Date of Amendment/

Restatement:
	  	July 6, 2012
		 	Expiration Date:	  	October 2, 2017 (5:00 p.m., California time)

 WHEREAS, on October 2, 2007, HYPERION THERAPEUTICS, INC. (the “Company”) issued a warrant
to purchase 300,000 shares of Series B Preferred Stock (the “Prior Warrant”) to COMERICA BANK, a Texas banking association, subsequently assigned to COMERICA VENTURES INCORPORATED, a California corporation, or its assignee
(“Holder”). 
 WHEREAS, on June 29, 2009, each one share of the Company’s issued and outstanding Series B
Preferred Stock was combined and reclassified into one share of the Company’s Common Stock (the “Reclassification”). 
 WHEREAS, on June 29, 2009, the Company also effected a reverse stock split whereby each issued and outstanding share of the Company’s Common Stock was reclassified and changed based on the ratio
of 1/179.5 fully paid and nonassessable shares of the Company’s Common Stock (the “Reverse Split”). 
 WHEREAS,
in accordance with the Reclassification and the Reverse Split, the Company’s Prior Warrant was converted into a warrant to purchase 1,671 shares of the Company’s Common Stock. 

WHEREAS, pursuant to the recapitalization, the Company and the Holder now desire to issue this warrant for Common Stock
(“Warrant”) which shall amend, restate and supersede the Prior Warrant. 
 THIS AMENDED AND RESTATED WARRANT TO
PURCHASE STOCK CERTIFIES THAT, for good and valuable consideration, the receipt of which is hereby acknowledged, Holder is entitled to purchase the number of fully paid and nonassessable shares of the class of securities (the “Shares”) of
the Company at the exercise price per Share (the “Warrant Price”) all as set forth above and as adjusted pursuant to this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. As used herein,
“Warrant Shares” shall mean the shares of 

 
Common Stock which Holder may acquire pursuant to this Warrant. 
 ARTICLE 1.
EXERCISE. 
 1.1 Method of Exercise. Holder may exercise this Warrant by delivering this Warrant and a duly
executed Notice of Exercise in substantially the form attached as Appendix 1 (the “Notice of Exercise”) to the principal office of the Company. Holder shall also deliver to the Company a check or wire for the aggregate Warrant Price for
the Shares being purchased. 
 1.2 Intentionally Omitted. 

1.3 Delivery of Certificate and New Warrant. Within 45 days after Holder exercises this Warrant, the Company shall deliver to
Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised and has not expired, a new warrant representing the Shares not so acquired. 
 1.4 Replacement of Warrants. In the case of loss, theft or destruction of this Warrant, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the
case of mutilation, on surrender and cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like terms and tenor. 

1.5 Acquisition of the Company. 
 1.5.1 “Acquisition.” For the purpose of this Warrant, “Acquisition” means (a) any sale, exclusive license, or other disposition of all or substantially all of the assets
(including intellectual property) of the Company, or (b) any reorganization, consolidation, merger or sale of the voting securities of the Company or any other transaction where the holders of the Company’s securities before the
transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction. 
 1.5.2 Assumption of Warrant. Upon the closing of any Acquisition (other than an Acquisition in which the consideration received by the Company’s stockholders consists solely of cash), and as a
condition precedent thereto, the successor or surviving entity shall assume the obligations of this Warrant, and this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise
of the unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price shall be adjusted accordingly, and the Warrant Price and number and class of Shares shall
continue to be subject to adjustment from time to time in accordance with the provisions hereof. 
 ARTICLE 2. ADJUSTMENTS TO THE SHARES.

 2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its Shares (or securities into which
Shares may be converted) payable in common stock, or other securities, or subdivides the outstanding common stock into a greater amount of common stock, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost
to Holder, the total number and kind of common stock or securities to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend or subdivision occurred. 

 2.2 Reclassification, Exchange or Substitution. Upon any reclassification, exchange,
substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and
kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event shall include any automatic conversion
of the outstanding or issuable securities of the Company of the same class or series as the Shares to common stock pursuant to the terms of the Company’s Certificate of Incorporation upon the closing of a registered public offering of the
Company’s common stock. The Company or its successor shall promptly issue to Holder a new warrant for such new securities or other property. The new warrant shall provide for adjustments or delivery of property which shall be as nearly
equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or property issuable upon exercise of the new warrant. The provisions
of this Article 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 
 2.3
Adjustments for Combinations, Etc. If the outstanding Shares are combined or consolidated, by reclassification, reverse split or otherwise, into a lesser Number of Shares, the Warrant Price shall be proportionately increased and the number of
Shares issuable under this Warrant shall be proportionately decreased. If the outstanding Shares are split or multiplied, by reclassification or otherwise, into a greater Number of Shares, the Warrant Price shall be proportionately decreased and the
number of Shares issuable under this Warrant shall be proportionately increased. 
 2.4 No Impairment. The Company shall
not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out all the provisions of this Article 2 and in taking all such action as may be necessary or
appropriate to protect Holder’s rights under this Article 2 against impairment. 
 2.5 Certificate as to
Adjustments. Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate signed by its Chief Financial Officer or Vice President of Finance setting forth
such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such
Warrant Price. 
 2.6 Fractional Shares. No fractional Shares shall be issuable upon exercise of this Warrant and the
Number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise of this Warrant, the Company shall eliminate such fractional share interest by paying Holder an amount computed
by multiplying the fractional interest by the fair market value, as determined by the Company’s Board of Directors, of a full Share. 

 ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties of the Company. The Company hereby represents and warrants to, and agrees with, the Holder as of
the Issue Date as follows: 
 3.1.1 The Company (i) is a corporation duly organized, validly existing, and
in good standing in its jurisdiction of incorporation, (ii) has the corporate power and authority to own and operate its properties and to carry on its business as now conducted and as proposed to be conducted; and (iii) is qualified as a
foreign corporation in all jurisdictions where such qualification is required. 
 3.1.2 The Company has all
requisite legal and corporate power and authority to execute, issue and deliver this Warrant, to issue the Shares issuable upon exercise or conversion of this Warrant, and to carry out and perform its obligations under this Warrant and any related
agreements. 
 3.1.3 All corporate action on the part of the Company, its officers, directors and stockholders
necessary for the authorization, execution, delivery and performance of its obligations under this Warrant and for the authorization, issuance and delivery of this Warrant and the Warrant Shares issuable upon exercise of this Warrant has been taken
and this Warrant constitutes the legally binding and valid obligation of the Company enforceable in accordance with its terms except as may be limited by applicable bankruptcy, insolvency reorganization or similar laws relating to or affecting the
enforcement of creditors’ rights. 
 3.1.4 Based upon the representations and warranties of the Holder, this
Warrant has been validly issued and is free of restrictions on transfer other than restrictions on transfer set forth herein and under applicable state and federal securities laws. The Warrant Shares issuable upon conversion of this Warrant, when
issued, sold and delivered in accordance with the terms of this Warrant for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable, will be issued in accordance with all applicable state and federal
securities laws; and will be free of restrictions on transfer other than restrictions on transfer under this Warrant and under applicable state and federal securities laws. Subject to applicable restrictions on transfer, the issuance and delivery of
this Warrant and the Warrant Shares issuable upon exercise or conversion of this Warrant are not subject to any preemptive or other similar rights or any liens or encumbrances except as specifically set forth in Company’s Certificate of
Incorporation, as amended, or this Warrant. Based upon the representations and warranties of the Holder, the offer, sale and issuance of the Warrant Shares, as contemplated by this Warrant, are exempt from the prospectus and registration
requirements of applicable United States federal and state security laws, and neither Company nor any authorized agent acting on its behalf has or will take any action hereafter that would cause the loss of such exemption. 

3.1.5 The execution, delivery, and performance of this Warrant will not result in (i) any violation of, be in
conflict with, or constitute a default under, with or without the passage of time or the giving of notice (A) any provision of the Company’s Certificate of Incorporation or By-laws (in each case as amended); (B) any provision of any
judgment, decree, or order to which the Company is a party, by which it is bound, or to which any of its material assets are subject; (C) any contract, obligation, or commitment to which the

 
Company is a party or by which it is bound; or (D) any statute, rule, or governmental regulation applicable to the Company, or (ii) the creation of any lien, charge or encumbrance upon
any assets of the Company. 
 3.1.6 The initial Warrant Price referenced on the first page of this Warrant is the
price per share of the Shares entered into in a negotiated transaction with third party investors prior to the Issue Date. 
 3.1.7 The Company’s capitalization table attached to this Warrant is true and complete and, reflects (i) all outstanding capital stock of the Company and (ii) all outstanding warrants,
options and other rights or agreements to purchase or otherwise acquire or issue any equity securities or convertible securities of the Company including this Warrant. 
 3.2 Representations and Warranties of Holder, With respect to the acquisition of this Warrant and any of the Shares Holder hereby represents and warrants to, and agrees with, the Company as
follows: 
 3.2.1 Purchase Entirely for Own Account. This Warrant is issued to Holder in reliance upon
Holder’s representation to the Company that this Warrant and the Shares will be acquired for investment for Holder’s, or its affiliate’s, own account, not as a nominee or agent, and not with a view to the resale or distribution of any
part thereof other than to an affiliate, and that Holder has no present intention of selling, granting any participation in, or otherwise distributing the same other than to an affiliate. By executing this Warrant, Holder further represents that
Holder does not have any contract, undertaking, agreement or arrangement with any person, other than an affiliate, to sell, transfer or grant participations to such person or to any third person with respect to any of the Shares. 

3.2.2 Reliance upon Holder’s Representations. Holder understands that this Warrant and the Shares are not
registered under the Act on the ground that the issuance of such securities is exempt from registration under the Act, and that the Company’s reliance on such exemption is predicated on Holder’s representations set forth herein.

 3.2.3 Accredited Investor Status. Holder represents to the Company that Holder is an Accredited
Investor (as defined in the Act). 
 3.2.4 Restricted Securities. Holder understands that this Warrant and
the Shares are “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such federal securities laws and applicable
regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances. 

3.3 Notice of Certain Events. If the Company proposes at any time (a) to declare any dividend or distribution upon its stock,
whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or
other rights; (c) to effect any reclassification or recapitalization of stock; (d) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate,
dissolve or wind up; or (e) take any other action covered by Article 1.5 or Article 2, then, in connection with each such event, the Company shall give Holder (1) at least 20 days 

 
prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of stock will be entitled
thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a), (b) and, as applicable (e) above; and (2) in the case of the matters referred to in (c), (d) and, as applicable, (e) above at
least 20 days prior written notice of the date then anticipated to be the closing or record date (and specifying the date on which the holders of stock will be entitled to exchange their stock for securities or other property deliverable upon the
occurrence of such event). 
 3.4 Information Rights. So long as the Holder holds this Warrant and/or any of the Shares,
the Company shall deliver to the Holder (a) promptly after mailing, copies of all communiques generally provided to holders of Series B Preferred Stock, (b) within one hundred twenty (120) days after the end of each fiscal year of the
Company, the annual audited financial statements of the Company certified by independent public accountants of recognized standing and, (c) if prepared by the Company within forty-five (45) days after the end of each of the first three
quarters of each fiscal year, the Company’s quarterly, unaudited financial statements. 
 3.5 Registration of Shares
Under the Act. The Company agrees that the Shares or, if the Shares are convertible into common stock of the Company, such common stock, shall be subject to the registration rights set forth on Exhibit A. 

ARTICLE 4. MISCELLANEOUS. 

4.1 Term; Exercise Upon Expiration. This Warrant is exercisable in whole or in part, at any time and from time to time on or before
the Expiration Date set forth above. The Company shall give Holder written notice of Holder’s right to exercise this Warrant not less than 90 days before the Expiration Date. If the notice is not so given, the Expiration Date shall
automatically be extended until 90 days after the date the Company delivers such notice to Holder. 
 4.2 Legends. This
Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 

(a) Warrant: THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 (b)
Shares: THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED
UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE 

 
TERMS AND CONDITIONS OF A CERTAIN INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE
COMPANY. 
 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERIIPICATE IS
SUBJECT TO, AND IN SOME CASES PROHIBITED BY, THE TERMS AND CONDITIONS OF A CERTAIN RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT BY AND AMONG THE STOCKHOLDER, THE CORPORATION AND CERTAIN HOLDERS OF STOCK OF THE CORPORATION. COPIES OF SUCH AGREEMENT
MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE CORPORATION. 
 THE SHARES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A VOTING AGREEMENT WHICH PLACES CERTAIN RESTRICTIONS ON THE VOTING OF THE SHARES REPRESENTED HEREBY. ANY PERSON ACCEPTING ANY INTEREST IN SUCH SHARES SHALL BE DEEMED TO AGREE TO AND SHALL BECOME
BOUND BY ALL THE PROVISIONS OF SUCH AGREEMENT. A COPY OF SUCH VOTING AGREEMENT WILL BE FURNISHED TO THE RECORD HOLDER OF THIS CERTIFICATE WITHOUT CHARGE UPON WRITTEN REQUEST TO THE COMPANY AT ITS PRINCIPAL PLACE OF BUSINESS. 

4.3 Compliance with Securities Laws on Transfer. This Warrant and the Warrant Shares issuable upon exercise of this Warrant (and
the securities issuable, directly or indirectly, upon conversion of the Warrant Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the
transferee. 
 4.4 Transfer Procedure. Subject to the provisions of Article 4.3, Holder may transfer all or part of this
Warrant or the Warrant Shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Warrant Shares, if any) by giving the Company notice of the portion of this Warrant being transferred
setting forth the name, address and taxpayer identification number of the transferee and surrendering this Warrant to the Company for reissuance to the transferee(s) (and Holder, if applicable); provided, however, that Holder may transfer all
or part of this Warrant to its affiliates, including, without limitation, Comerica Incorporated and its affiliates, at any time without notice or the delivery of any other instrument to the Company, and such affiliate shall then be entitled
to all the rights of Holder under this Warrant and any related agreements, and the Company shall cooperate fully in ensuring that any stock issued upon exercise of this Warrant is issued in the name of the affiliate that exercises this Warrant. The
terms and conditions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the holders hereof and their respective permitted successors and assigns. Unless the Company is filing financial information with the SEC
pursuant to the Securities Exchange Act of 1934, the Company shall have the right to refuse to transfer any portion of this Warrant to any person who directly competes with the Company. 

4.5 Notices. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and
effective when given personally or mailed by first-

 
class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or such Holder from
time to time. All notices to the Holder shall be addressed as follows: 
 COMERICA VENTURES INCORPORATED 

Attn: Warrant Administrator 
 1717 Main Street 
 5th Floor, MC 6406 

Dallas, Texas 75201 
 All notices to the Company shall be addressed as follows: 
 HYPERION THERAPEUTICS,
INC. 
 601 Gateway Blvd., Suite 200 
 South San Francisco, CA 94080 
 Attn: Chief Financial Officer 

4.6 Amendments. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 
 4.7
Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such
dispute, including reasonable attorneys’ fees. 
 4.8 Governing Law. This Warrant shall be governed by and construed
in accordance with the laws of the State of California, without giving effect to its principles regarding conflicts of law. 

4.9 No Other Agreements. This Warrant constitutes the full and entire understanding and agreement between the parties with respect
to the subject hereof, and supersedes all prior negotiations, agreements and understandings with respect thereto. Neither this Warrant nor any term hereof may be amended, waived, discharged or terminated verbally, but only by a written instrument
signed by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought. 
 4.10
Confidentiality. The Company hereby agrees to keep the terms and conditions of this Warrant confidential. Notwithstanding the foregoing confidentiality obligation, the Company may disclose information relating to this Warrant as required by
law, rule, regulation, court order or other legal authority, provided that (i) the Company has given Holder at least ten (10) days’ notice of such required disclosure, and (ii) the Company only discloses information that is
required, in the opinion of counsel reasonably satisfactory to Holder, to be disclosed. 
 [Balance of Page Intentionally
Left Blank] 

 IN WITNESS WHEREOF, the undersigned parties acknowledge and agree to accept this Warrant as
the replacement warrant for the Prior Warrant. 
  

			
	HYPERION THERAPEUTICS, INC.
		
	By:	 	/s/ Donald J. Santel
	Name:	 	Donald J. Santel
	Title:	 	Chief Executive Officer

  

			
	COMERICA VENTURES INCORPORATED
		
	By:	 	/s/ LaReeda Rentie
	Name:	 	LaReeda Rentie
	Title:	 	Assistant Vice President

 [Signature Page to Warrant to Purchase Stock] 

 APPENDIX 1 
 NOTICE OF EXERCISE 
 1. The undersigned hereby irrevocably elects to
purchase                      shares of Common Stock of HYPERION THERAPEUTICS, INC. pursuant to the terms of the attached Warrant, and tenders
herewith payment of the purchase price of such shares in full. 
 2. Please issue a certificate or certificates representing
said shares in the name of the undersigned or in such other name as is specified below: 
 Comerica Ventures Incorporated

 ATTN: Warrant Administrator 
 1717 Main Street 
 5th Floor, MC 6406 

Dallas, Texas 75201 
 3. The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view toward the resale or distribution thereof except in
compliance with applicable securities laws. 
  

					
	COMERICA VENTURES INCORPORATED or Assignee	 	
		
	  	 	
		 	(Signature)
		
	 	 	
		 	(Name and Title)
		
	 	 	
		 	(Date)

 EXHIBIT A 
 Registration Rights 
 The Shares (if common stock), or the common stock
issuable upon conversion of the Shares, shall be deemed “Registrable Securities” or otherwise entitled to “piggy back” registration rights in accordance with the terms of the following agreement (the “Agreement”)
between the Company and its Preferred Stock investor(s): 
 Investor Rights Agreement dated August 24, 2007, as amended

 The Company agrees that no amendments will be made to the Agreement which would have a disparate adverse impact on
Holder’s registration rights thereunder in comparison to the other holders of the Shares, without the consent of Holder. Upon exercise of the Warrant to which this Exhibit A is attached, Holder shall become a party to the Agreement solely for
the purpose of the above-mentioned registration rights.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]